Sleep disturbances are among the most common and most stubborn burdens carried by women undergoing chemotherapy for breast cancer. Pain, nausea, anxiety, hormonal upheaval, and the sheer stress of a cancer diagnosis all conspire to fragment the night, leaving patients exhausted at the very moment their bodies most need restorative rest. Now a randomized controlled trial from researchers at Jiangnan University’s Wuxi School of Medicine, published in Supportive Care in Cancer, offers an unexpectedly simple countermeasure: structured education about eating an anti-inflammatory diet. Over twelve weeks, women who learned how to shift their diets toward less inflammatory patterns slept measurably better, showed calmer inflammatory blood profiles, and reported a better overall quality of life than patients who received usual care alone.
The trial enrolled 132 breast cancer patients who were undergoing chemotherapy and who already suffered from sleep disturbances. Participants were randomly assigned to one of two groups. The intervention group received a twelve-week anti-inflammatory dietary education program built around the energy-adjusted dietary inflammatory index, or E-DII, a scoring system that quantifies the inflammatory potential of a person’s diet based on their intake of dozens of nutrients and food components. The control group continued with usual care. Sleep quality was assessed at baseline and again at twelve weeks using the Pittsburgh Sleep Quality Index, a widely validated questionnaire that captures everything from how long it takes to fall asleep to how often sleep is interrupted and how rested people feel in the morning.
The results were striking. In the completer analysis, which included the 116 participants, or 87.9 percent, who finished the twelve-week assessment, the proportion of patients still experiencing significant sleep disturbance, defined as a PSQI score of eight or higher, fell to 49.2 percent in the dietary education group. In the control group, the figure remained at 78.9 percent, a difference the authors report as highly statistically significant. In other words, roughly half of the women who learned to eat in an anti-inflammatory way no longer met the threshold for disturbed sleep by the end of the study, compared with fewer than a quarter of those who did not receive the education.
The continuous data reinforce that headline finding. Using linear mixed-effects models under the intention-to-treat principle, the researchers calculated that the intervention group achieved a greater reduction in PSQI scores than controls, with a beta coefficient of minus 2.10 and a 95 percent confidence interval spanning minus 3.01 to minus 1.18. A drop of more than two points on the PSQI is clinically meaningful, reflecting improvements across multiple dimensions of sleep rather than a single narrow measure. The intervention group also showed a significantly lower E-DII score, confirming that the education program genuinely changed what participants ate, shifting their diets toward components associated with reduced systemic inflammation.
Perhaps the most compelling evidence comes from the blood. Levels of interleukin-1 beta, interleukin-6, and C-reactive protein, all well-established markers of systemic inflammation, fell significantly in the intervention group, while interleukin-10, an anti-inflammatory cytokine, rose. All of these changes reached statistical significance. This biomarker profile matters because it links the behavioral intervention to a plausible biological mechanism. Sleep regulation is intimately entwined with the immune system; cytokines such as interleukin-1 beta and interleukin-6 are not merely markers of inflammation but active participants in the physiological signaling that governs sleep and wakefulness. When inflammatory signaling runs hot, sleep architecture suffers, and disturbed sleep in turn feeds back into higher inflammation, creating a vicious cycle.
That cycle is particularly relevant during chemotherapy. Previous work has shown that fatigue and poor sleep quality in breast cancer patients undergoing treatment are associated with changes in inflammatory markers, and systematic reviews have documented that sleep disturbances affect a large share of breast cancer survivors, often persisting for years after diagnosis. Chemotherapy itself can provoke inflammatory responses, and the psychological weight of cancer treatment adds further fuel. A dietary approach that measurably lowers inflammatory load therefore offers a rationale that goes beyond correlation. The Jiangnan University team had earlier reported cross-sectional evidence suggesting that inflammation may mediate the association between a pro-inflammatory diet and sleep disturbance in breast cancer patients, and the new trial was designed to test that hypothesis prospectively.
The intervention’s design is notable for its pragmatism. Rather than prescribing a rigid meal plan, the program educated patients on the principles of the dietary inflammatory index, teaching them which foods and nutrients push the index upward, such as those typical of highly processed, energy-dense eating patterns, and which pull it downward, including components abundant in Mediterranean-style diets rich in vegetables, fruit, whole grains, and unsaturated fats. Prior observational studies have repeatedly linked Mediterranean-style eating and higher diet quality to better sleep, and randomized trials in other populations, including overweight men with chronic insomnia symptoms and women with type 2 diabetes following the DASH diet, have reported sleep benefits from dietary change. The new study extends this evidence into the demanding context of active cancer treatment, where appetite changes, nausea, and fatigue make dietary modification especially challenging.
Quality of life improved alongside sleep. The intervention group showed a significantly greater gain in overall quality of life, measured with a validated breast cancer-specific instrument, with a beta of 14.07 and a confidence interval of 8.61 to 19.52. This is not a trivial side benefit. Poor sleep during chemotherapy is linked to worse fatigue, mood disturbance, and treatment tolerance, and improving it can ripple through nearly every aspect of a patient’s daily functioning. The fact that a dietary education program, delivered without drugs and without intensive clinical monitoring, produced simultaneous improvements in sleep, inflammation, and quality of life suggests a low-cost, scalable adjunct to standard supportive care.
Certain caveats deserve attention. The completer analysis of the sleep disturbance proportions included only participants who finished the study, which can introduce bias if dropouts differ systematically between groups, although the intention-to-treat models for continuous outcomes mitigate this concern. The twelve-week follow-up cannot say whether benefits persist after the education program ends or after chemotherapy concludes. And because the intervention combined education with dietary change, the trial cannot fully disentangle the effect of knowledge from the effect of the diet itself. The authors also note that raw data are available upon reasonable request, and the trial was prospectively registered with the Chinese Clinical Trial Registry, both markers of methodological transparency.
Even with those limitations, the study adds an important piece to a rapidly growing picture of diet as a modifiable lever on sleep health. Systematic reviews have connected pro-inflammatory dietary patterns to poorer sleep quality, duration, and timing, and anti-inflammatory diets have been shown to lower inflammatory markers in randomized trials across adult populations. For the millions of women worldwide who face breast cancer, a disease whose global burden continues to climb according to the latest GLOBOCAN estimates, the message from this trial is quietly revolutionary: the plate, not just the pharmacy, may be part of the answer to the sleepless nights of chemotherapy. Larger and longer trials will be needed to confirm durability and to identify which patients benefit most, but the trial, funded by the National Natural Science Foundation of China and conducted under the Declaration of Helsinki with informed consent from all participants, makes a strong case that teaching patients to eat anti-inflammatorily is a worthwhile, evidence-based investment in their rest and recovery.
Subject of Research: Effects of anti-inflammatory dietary education on sleep disturbances and inflammatory biomarkers in breast cancer patients undergoing chemotherapy
Article Title: Effects of anti-inflammatory dietary education on sleep disturbances among patients with breast cancer undergoing chemotherapy: A randomized controlled trial
Article References: Cheng, L., Huang, Z., He, J., Cheng, X., Wang, Y., Lin, X., Miao, X., Wang, R., & Xia, S. (2026). Effects of anti-inflammatory dietary education on sleep disturbances among patients with breast cancer undergoing chemotherapy: A randomized controlled trial. Supportive Care in Cancer, 34(11), Article 1082. https://doi.org/10.1007/s00520-026-11332-3
Image Credits: AI Generated
DOI: 10.1007/s00520-026-11332-3
Keywords: breast cancer, chemotherapy, sleep disturbance, anti-inflammatory diet, dietary inflammatory index, inflammation, randomized controlled trial, Pittsburgh Sleep Quality Index, quality of life, cytokines, nutritional education, supportive care
News Source: Nathaniel Bowman. (October 11, 2026). Anti-Inflammatory Diet Eases Chemotherapy-Related Sleep Problems in Breast Cancer Patients, Trial Finds. Scienmag.
